Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Marie‐Claude Hofmann(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 49
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|507
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
|Journal of the National Comprehensive Cancer Network|2018|370